Tag: Immunotherapeutics
OSE Immunotherapeutics announces new public aid to support its innovation and research programs in the field of RNA Therapeutics – 08/01/2023 at 07:30
Nantes, France – August 1, 2023, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that the Company has received innovation aid of 200,000 euros from the French…
OSE Immunotherapeutics: publication on OSE-230 in ‘Frontiers in Immunology’
By Alexandra Saintpierre Published on 07/19/2023 at 6:33 p.m. (Boursier.com) — OSE Immunotherapeutics SA announces the publication,…
OSE Immunotherapeutics: new publication on the OSE-230 antibody – 07/19/2023 at 18:21
(AOF) – OSE Immunotherapeutics announces the publication of the latest results on the pro-resolving monoclonal antibody OSE-230, an innovative new approach in the resolution of severe and chronic inflammation, in…
OSE Immunotherapeutics: new publication on the OSE-230 antibody
(AOF) – OSE Immunotherapeutics announces the publication of the latest results on the pro-resolving monoclonal antibody OSE-230, an innovative new approach in the resolution of severe and chronic inflammation, in…
OSE Immunotherapeutics receives €1.5 million in funding from Bpifrance for the development of a companion diagnostic test associated with Tedopi®, its vaccine against non-small cell lung cancer – 06/20/2023 at 18:00
• Funding of 1.5 million euros from Bpifrance – Regional Direction of Nantes within the framework of the “R&D Innovation Loan” program. • Development of a companion diagnostic test to…
Oncology: OSE Immunotherapeutics receives 1.5 million euros from Bpifrance – 06/20/2023 at 18:07
(AOF) – OSE Immunotherapeutics announces today that it has received non-dilutive funding of 1.5 million euros from Bpifrance. The “R&D Innovation Loan” program aims to support the development of a…
OSE Immunotherapeutics presents the latest data on the BiCKI®IL-7, CLEC-1 and OSE-230 preclinical programs in Immuno-Oncology and Immuno-Inflammation At international conferences – 06/15/2023 at 07:30
Nantes, France – June 15, 2023, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that the latest scientific data has been selected for oral or poster presentations…
The Board of Directors of OSE Immunotherapeutics proposes the appointment of Éric Leire as a new independent director – 05/31/2023 at 18:00
To the General Shareholders’ Meeting of June 22, 2023 Nantes, May 31, 2023, 6 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Ticker: OSE) announces that the Board of Directors, on…
OSE Immunotherapeutics: end of recruitment for the Tedopi trial – 2023-05-24 at 18:13
(AOF) – OSE Immunotherapeutics SA announces the end of recruitment in the TEDOPaM phase 2 clinical trial, promoted and conducted by the Gercor group, which is evaluating Tedopi in advanced…
OSE Immunotherapeutics pursues clinical development in ulcerative colitis with full worldwide rights to Lusvertikimab – 05/12/2023 at 18:00
• Lusvertikimab (OSE-127), a ‘first-in-class’ product, is the most clinically advanced anti-IL-7R monoclonal antibody. • Ongoing phase 2 trial in ulcerative colitis (sponsor OSE Immunotherapeutics) after a positive futility analysis…
OSE Immunotherapeutics alone continues its clinical study on Lusvertikimab – 05/12/2023 at 18:11
(AOF) – OSE Immunotherapeutics announces that it is continuing its phase 2 clinical study of Lusvertikimab having obtained full worldwide rights to the product. OSE and Servier signed a two-step…
OSE Immunotherapeutics: positive clinical results against ulcerative rectolitis – 02/22/2023 at 18:13
(AOF) – OSE Immunotherapeutics announces the publication in “The Journal of Immunology” of positive Phase 1 clinical results of OSE-127/S95011, an IL-7 receptor (IL-7R) antagonist, developed in partnership with Servier.…